FIRST RUSSIAN EXPERIENCE OF EARLY CONVERSION TO EVEROLIMUS IN THE KIDNEY TRANSPLANTATION FROM EXPANDED CRITERIA DONORS: A SUMMARY OF 5-YEAR OBSERVATION

Introduction. Kidney transplant (KTx) with reduced functional reserve is more sensitive to the  toxic effects of calcineurin inhibitors (CNI). Immunosuppressive (IST) approach included m-TOR inhibitors in case of KTx from the ECD lead to decreasing levels of cyclosporine (CsA) in the blood. Despite of presence international pilot studies we having not yet strong recommendation for real  combination of CsA and  Everolimus. In this  article we presented 5-yeras results of the  first Russian experience of systematic use Everolimus as basic IST in KTx from  ECDs. 

Patients  and methods.  The group of recipients (n=41) was formed during the operation; received a bilateral kidney transplants from the same ECDs. Comparison group (n=19) received standard IST consisting of CsA, MMF and  steroids. Study group included 22 recipients who received an another kidney  from the same ECD and  IST, based on early (starting from the 90th  day after  transplantation) conversion from MMF to Everolimus-1.5mg/day (target concentration-3-6ng/mL). Simultaneously with the appointment Everolimus, dosing occurred immediately Neoral decrease by 50% and  then, in accordance with the target concentration (C0-30-50ng/ml). Implementing a program of gradual minimization of the dose steroids in patients of the study group.

Results. Both groups were comparable in terms of level of serum creatinine and glomerular filtration rate of up to 3 months after transplantation. As a result of the introduction of a new scheme of ICN in the study group, for the 60-month observation GFR study group was 46±15 ml/min/1.73m², the control is reduced to 28±7  ml/min/1.73m²;P<0.05.

Conclusion. Early administration of Everolimus is strongly recommended in all cases of the use of grafts for KTx obtained from the ECDs. This approach helps to minimize of nephrotoxity of CNT, provides the prevention of chronical transplant nephropathy, the  stable renal  function, and  contributes to the  survival and  renal  transplant recipients.

1. Nankivell BJ, Borrows RJ, Fung CL et al. The Natural History of Chronic Allograft Nephropathy. N Engl J Med 2003; 349(24):2326-2333

2. Naesens M, Kuypers DRJ, Sarwal M et al. Calcineurin Inhibitor Nephrotoxicity. Clin J Am Soc Nephrol 2009 Feb;4(2):481-508

3. Chapman JR. Chronic Calcineurin Inhibitor Nephrotoxicity–Lest We Forget. Am J Transplant 2011;11(4):693-697

4. Nankivell BJ, Wavamunno MD, Borrows RJ et al. Mycophenolate Mofetil Is Associated with Altered Expression of Chronic Renal Transplant Histology. Am J Transplant 2007; 7(2):366-376

5. Holdaas H, Midtvedt K, Asberget A. A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf 2012;11(6):1013-1022

6. Brazelton TR, Morris R. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996;8(5):710-720

7. Grinyo JM, Bestard O, Torras J, Cruzado JM. Optimal immunosuppression to prevent chronic allograft dysfunction. Kidney Int 2010; 78, suppl.119: S66-70

8. Brouard S, Renaudin K, Soulillou JP. Revisiting the natural history of IF/TA in renal transplantation. Am J Transpl 2011; 11: 647-649

9. Matas AJ. Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am J Transpl 2011; 11:687-692

10. Tedesco-Silva H Jr, Vitko S, Pascual J et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007; 20(1):27-36

11. Tedesco-Silva H.Jr, Cibrikb D, Johnstonc T et al. Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal Transplant Recipients. Am J Transplan 2010; 10: 1401–1413

12. Cibrik D, Tedesco -Silva Jr H, Vathsala A et al. Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation. Transplantation 2013; 95(7): 933-942

13. Kahan BD, Sheena G, Tejpal N et al. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51(1):232-239

14. Резник ОН, Багненко СФ, Мойсюк ЯГ и др. Трансплантация почек от возрастных доноров. Актуальность, первый опыт и перспективы. Вестн трансплантол и искусственных органов 2009;1:11-22. [Reznik ON, Bagnenko SF, Moysyuk YaG i dr. Transplantatsiya pochek ot vozrastnykh donorov. Aktual'nost', pervyy opyt i perspektivy. Vestnik transplantologii i iskusstvennykh organov 2009;1:11-22]

15. Cohen B, Smits JM, Haase B et al. Expanding the donor pool to increase renal transplantation. Nephrol Dial Transpl 2005; 20:34-38

16. Meier-Kriesche H, Schold JD, Gaston RS et al. Kidneys from deceased donors: maximizing the value of a scarce resource. American J Of Transplantation 2005;5:1725-1730

17. Nicholson MJ. Renal transplantation from non-heartbeating donors: Opportunities and Challenges. Transplantation Reviews 2000;14(1):1-17

18. Arns W, Citterio F, Campistol JM. “Old-for-old” – new strategies for renal transplantation. Neprol DialTransplant 2007;22: 336-341

19. Carter JT, Chan S, Roberts JP. Expanded criteria donor kidney allocation: marked decrease in cold ischemia and delayed graft function at a single center. American J. of Transplantation 2005;5:2745-2753

20. Danovitch GM, Gaston RS et al. The report of a national conference on the wait list for kidney transplantation. Am J Transplant 2003;3(7): 775-785

21. Delmonico FL, Wynn JJ. Managing the enlarging waiting list. Am J Transplant 2002;2:889-890

22. Port F. Expanded criteria donors for kidney transplantation. Am J Transpl 2003;3(l4): 114-125

23. Sung RS, Guidinger MK, Lake CD. Impact of the expanded criteria donor allocation system on the use of expanded criteria donor kidneys. Transplantation 2005;79(9):1257-1261

24. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialisys, patients on dialisys waiting transplantation and recipients of a first cadaveric transplant. NEnglJMed 1999; 341:1725-1729

25. Резник ОН, Тутин АП, Ульянкина ИВ. Минимизация иммуносупрессии при трансплантации почки. В естн трансплантол и искусственных органов 2011; XIII(4): 66–75. [ReznikON, TutinAP, Ul'yankinaIV. Minimizatsiya immunosupressii pri transplantatsii pochki. Vestnik transplantologii i iskusstvennykh organov 2011; XIII(4): 66–75]

26. Martins PNA, Pratschke J, Pascher A et al. Age and immune response in organ transplantation. Transplantation 2005; 79:127-132

27. Matas AJ, Lawson W, McHugh L et al. Employment patterns after successful kidney transplantation. Transplantation 1996;61:729-733

28. Meier-Kriesche HU, Ojo A, Hanson J et al. Exponentially insceased risk of infectious death in older transplant recipients. Kidney Int 2001;59:1539

29. Li YT, Danguilan RA, Cabanayan-Casasola CB et al. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: philippine experience. Transplantation Proceedings 2008;40:2211-2213

30. Luke PPW, Nguan CY, Horovitz D. Immunosupression without calcineurin inhibition: optimization of renal function in expanded criteria donor renal transplantation. Clin Transplant 2008;10:1-7

31. Arns W, Citterio F, Campistol JM. «Old-for-old» – new strategies for renal transplantation. Neprol Dial Transplant 2007; 22: 336-341

32. Grinyo JM, Bestard O, Torras J, Cruzado JM. Optimal immunosuppression to prevent chronic allograft dysfunction. KidneyInt 2010; 78, suppl.119: S66-70

33. Прокопенко ЕИ. Применение эверолимуса у denovo реципиентов почечного трансплантата. Вестн трансплантол и искусственных органов 2010;2: 74-82. [ProkopenkoEI. Primenenie everolimusa u de novo retsipientov pochechnogo transplantata / Vestnikt ransplantologii i iskusstvennykh organov. 2010;2: 74-82]

34. Fellstrom B. Cyclosporine nephrotoxicity. Transplantation Proceedings 2004; 36: 220S-223S

35. Giron F, Baez Y, Niño-Murcia A et al. Conversion Therapy to Everolimus in Renal Transplant Recipients: Results After One Year. Transplant Proc 2008; 40: 711-713

36. Inza A, Balda S, Álvarez E et al. Conversion to Everolimus in Kidney Transplant Recipients with Decreased Renal Function. Transplant Proc 2009;41: 2134–2136

37. Pascual J. The use of everolimus in renal-transplant patients. International Journal of Nephrology and Renovascular Disease 2009; 2: 9–21

38. Mjornstedta L, Sørensenb SS, von zur Muhlenc B et al. Improved Renal Function after Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation. Am J Transplant 2012; 12(10): 2744-2753

39. Pascual J et al. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplantation Reviews 2006; 20: 1–18

40. Pascual J, Srinivas TR, Chadban S et al. TRANSFORM: a novel study design to evaluate the effect of everolimus on longterm outcomes after kidney transplantation. Open Access J of Clinical Trials 2014; 6: 45-54

41. Tu Y, Stepkowski SM, Chou TC, Kahan BD. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 1995; 59: 177-183

42. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6: 39-87

43. Holdaas H, Midtvedt K, Asberget A. A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf 2012;11(6):1013-1022

44. Vitko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005;5:2521-2530

45. Nashan B, Curtis J, Ponticelli C et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004;78:1332-1340

46. Lorber MI, Mulgaonkar S, Butt KMH et al. Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study: Transplantation 2005; 80: 244–252

47. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2:850-856

48. Brennan DC, Legendre C, Patel D et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011; 11:2453-2462

49. Langer RM, Hene R, Vitko S et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicenter trial in renal transplantation. Transpl Int 2012; 25: 592–602

50. Kovarik JM et al. Differential Pharmacokinetic Interaction of Tacrolimus and Cyclosporine on Everolimus. TransplantProc 2006; 38: 3456–3458